Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of New-Onset atrial fibrillation after cardiac surgery

Angiology

Volumn 65, Issue 4, 2014, Pages 294-297

  Simopoulos, Vassilios ^a   Tagarakis, Georgios I ^a   Daskalopoulou, Stella S ^b   Daskalopoulos, Marios E ^c   Lenos, Aristidis ^d   Chryssagis, Konstantinos ^d   Skoularingis, Ioannis ^a   Molyvdas, Paschalis Adam ^a   Tsilimingas, Nikolaos B ^a   Aidonidis, Isaac ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b MCGILL UNIVERSITY   (Canada)

^c THRIASIO GENERAL HOSPITAL   (Greece)

^d Department of Cardiac Surgery Heart and Vessels Clinic Bad Neustadt   (Germany)

Author keywords

amiodarone; atrial fibrillation; cardiac surgery; postoperative atrial fibrillation; ranolazine

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATORVASTATIN; METOPROLOL; PERINDOPRIL; POTASSIUM; RANOLAZINE; WARFARIN;

AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; EXTRACORPOREAL CIRCULATION; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; LOADING DRUG DOSE; MALE; MONOTHERAPY; OPERATION DURATION; POSTOPERATIVE ATRIAL FIBRILLATION; POSTOPERATIVE COMPLICATION; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

AMIODARONE; ATRIAL FIBRILLATION; CARDIAC SURGERY; POSTOPERATIVE ATRIAL FIBRILLATION; RANOLAZINE;

ACETANILIDES; ADMINISTRATION, ORAL; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GREECE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SURGICAL PROCEDURES, ELECTIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84895453018     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713477911     Document Type: Article

References (33)

1. Bandeali SJ, Kayani WT, Lee VV, et al. Outcomes of preoperative angiotensin-converting enzyme inhibitor therapy in patients undergoing isolated coronary artery bypass grafting. Am J Cardiol. 2012 ; 110 (7). 919-923
2. Radaelli G, Bodanese LC, Guaragna JC, et al. The use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of CABG. Rev Bras Cir Cardiovasc. 2011 ; 26 (3). 373-379
3. Ouzounian M, Buth KJ, Valeeva L, Morton CC, Hassan A, Ali IS. Impact of preoperative angiotensin-converting enzyme inhibitor use on clinical outcomes after cardiac surgery. Ann Thorac Surg. 2012 ; 93 (2). 559-564
4. Rostagno C. Atrial fibrillation in patients undergoing surgical revascularization: an update on pharmacologic prophylaxis. Cardiovasc Hematol Agents Med Chem. 2012 ; 10 (4). 325-338
5. Heldal M, Atar D. Pharmacological conversion of recent onset atrial fibrillation: a systematic review. Scand Cardiovasc J. 2013 ; 47 (1). 2-10
6. Mitchell LB. CCS Atrial Fibrillation Guidelines Committee. Canadian cardiovascular society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol. 2011 ; 27 (1). 91-97
7. Echahidi N, Pibarot P, O'Hara G, Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008 ; 51 (8). 793-801
8. Sabzi F, Zokaei AH, Moloudi AR.. Predictors of atrial fibrillation following coronary artery bypass grafting. Clin Med Insights Cardiol. 2011 ; 5: 67-75
9. Hogue CW, Hyder ML. Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. Ann Thorac Surg. 2000 ; 69 (1). 300-306
10. Cao L, Li Q, Bi Q, Yu QJ.. Risk factors for recurrent stroke after coronary artery bypass grafting. J Cardiothorac Surg. 2011 ; 6: 157
11. Banach M, Kourliouros A, Reinhart KM, et al. Postoperative atrial fibrillation - what do we really know?. Curr Vasc Pharmacol. 2010 ; 8 (4). 553-572
12. Banach M, Mariscalco G, Ugurlucan M, Mikhailidis DP, Barylski M, Rysz J. The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation - still underestimated opponent. Europace. 2008 ; 10 (11). 1266-1270
13. McCormack JG, Stanley WC, Wolff AA. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol. 1998 ; 30 (5). 639-645
14. Phelps CE, Buysman EK, GomezRey G. Costs and clinical outcomes associated with use of ranolazine for treatment of angina. Clin Ther. 2012 ; 34 (6). 1395-1407
15. Bonadei I, Vizzardi E, Quinzani F, et al. Effects of ranolazine on cardiovascular system. Recent Pat Cardiovasc Drug Discov. 2011 ; 6 (3). 215-221
16. Vizzardi E, D'Aloia A, Quinzani F, et al. A focus on antiarrhythmic properties of ranolazine. J Cardiovasc Phramacol Ther. 2012 ; 17 (4). 353
17. Hancox JC, Doggrell SA. Perspective: does ranolazine have potential for the treatment of atrial fibrillation?. Expert Opin Investig Drugs. 2010 ; 19 (12). 1465-1474
18. Aidonidis I, Doulas K, Hatziefthimiou A, et al. Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther. 2013 ; 18 (1). 94-101
19. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008 ; 5 (7). 1019-1026
20. Carvas M, Nascimento BC, Acar M, Nearing BD, Belardinelli L, Verrier RL. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J Cardiovasc Pharmacol. 2010 ; 55 (3). 286-291
21. Nieminen T, Nanbu DY, Datti IP, et al. Antifibrillatory effect of ranolazine during severe stenosis in the intact porcine model. Heart Rhythm. 2011 ; 8 (4). 608-614
22. Tagarakis GI, Aidonidis I, Daskalopoulou SS, et al. Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery[published online November 7, 2012]. Curr Vasc Pharmacol. 2012 ;:
23. Belardinelli L, Shryock JC, Fraser H.. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current ranolazine. Heart. 2006 ; 92 (suppl 4). iv6 - iv14
24. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007 ; 116 (13). 1449-1457
25. Davidenko JM, Antzelevitch C.. Electrophysiological mechanisms underlying rate-dependent changes of refractoriness in normal and segmentally depressed canine Purkinje fibers. The characteristics of postrepolarization refractoriness. Circ Res. 1986 ; 58 (2). 257-268
26. Kirchhof PF, Fabritz CL, Franz MR. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. Circulation. 1998 ; 97 (25). 2567-2574
27. Koller BS, Karasik PE, Solomon AJ, Franz MR. Relation between repolarization and refractoriness during programmed electrical stimulation in the human right ventricle. Implications for ventricular tachycardia induction. Circulation. 1995 ; 91 (9). 2378-2384
28. Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012 ; 110 (5). 673-677
29. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for less Ischemia in non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009 ; 53 (17). 1510-1516
30. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes. 2008 ; 1 (2). 107-115
31. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007 ; 116 (15). 1647-1652
32. Dhalla AK, Wang WQ, Dow J, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009 ; 297 (5). H1923 - H1929
33. Frommeyer G, Kaiser D, Uphaus T, et al. Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. Heart Rhythm. 2012 ; 9 (12). 2051-2058